In biotech, competitive lines are often drawn in the lab. Increasingly, they are drawn in patent court. This week, Enveric Biosciences announced that a Post Grant Review petition filed against its U.S. Patent No. 12,138,276 has been formally withdrawn. The petition, initially filed by Gilgamesh Pharmaceuticals, was later inherited by AbbVie Inc. following AbbVie’s acquisition of Gilgamesh in a transaction valued at up to 1.2 billion dollars centered on the clinical stage compound bretisilocin.
